GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Global Cord Blood Corp (OTCPK:CORBF) » Definitions » EBITDA per Share

Global Cord Blood (Global Cord Blood) EBITDA per Share : $0.78 (TTM As of Mar. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Global Cord Blood EBITDA per Share?

Global Cord Blood's EBITDA per Share for the three months ended in Mar. 2022 was $0.18. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $0.78.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Global Cord Blood's EBITDA per Share or its related term are showing as below:

CORBF's 3-Year EBITDA Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.9
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Global Cord Blood's EBITDA for the three months ended in Mar. 2022 was $22.4 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Global Cord Blood EBITDA per Share Historical Data

The historical data trend for Global Cord Blood's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Cord Blood EBITDA per Share Chart

Global Cord Blood Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.53 0.71 0.75 0.85

Global Cord Blood Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.20 0.20 0.19 0.18

Global Cord Blood EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Global Cord Blood's EBITDA per Share for the fiscal year that ended in Mar. 2022 is calculated as

EBITDA per Share(A: Mar. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=103.519/121.551
=0.85

Global Cord Blood's EBITDA per Share for the quarter that ended in Mar. 2022 is calculated as

EBITDA per Share(Q: Mar. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=22.403/121.466
=0.18

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Global Cord Blood  (OTCPK:CORBF) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Global Cord Blood EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Global Cord Blood's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Global Cord Blood (Global Cord Blood) Business Description

Traded in Other Exchanges
N/A
Address
1 Garden Road, 48th Floor, Bank of China Tower, Central, Hong Kong, HKG
Global Cord Blood Corp provides cord blood banking services. The company provides cord blood processing and storage services for expectant parents interested in capturing the evolving medical treatments and technologies such as cord blood transplants.
Executives
Kent C Mccarthy 10 percent owner, other: Mbr 13(d) grp own 10% plus 930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Private Equity Fund Ii Lp 10 percent owner 5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205
7-2010 Grat 5 Under Kent C. Mccarthy Grat Tr Dtd 4-23-2010 other: 13 (d) group owning > 10% 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
7-2010 Grat 6 Under Kent C Mccarthy Grat Tr Dtd 4-23-2010 10 percent owner, other: Member of 13(d) group owning m 7335 COTTONWOOD, SHAWNEE KS 66216
Mccarthy Family Sd, Llc 10 percent owner, other: 13 (d) group owning > 10% 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jhab Fund Ii, Llc other: 13(d) group owning > 10% 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jhab Management Ii, Llc other: 13(d) group owning > 10% 7335 COTTONWOOD DRIVE, SHAWNEE KS 66216
Jcf Co Lf, L.p. other: 13(d) group owning > 10% 930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Capital Management Llc other: Member of the group 13021 W 74TH ST, SHAWNEE KS 66216
Jayhawk China Fund Cayman Ltd other: Member of the group 930 TAHOE BLVD., 802-281, INCLINE VILLAGE NV 89451
Jayhawk Private Equity Gp Ii, L.p. 10 percent owner 5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205
Jayhawk Private Equity, Llc 10 percent owner 5410 WEST 61ST PLACE, SUITE 100, MISSION KS 66205

Global Cord Blood (Global Cord Blood) Headlines

From GuruFocus